Gossamer Bio (GOSS) Cash from Financing Activities (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Cash from Financing Activities of $512000.0 for Q1 2026, up 1.59% year-over-year from $504000.0 in Q1 2025, and down 87.05% quarter-over-quarter from $4.0 million in Q4 2025.
Gossamer Bio (GOSS) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Gossamer Bio's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $512000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 1.59% year-over-year to $512000.0; the TTM figure through Mar 2026 stood at $6.4 million (up 176.32% YoY), while the FY2025 annual figure was $6.4 million, up 155.93% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $512000.0, down from $4.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $198.5 million in Q3 2023, with the low at -$9.2 million in Q2 2024.
- The 5-year median for Cash from Financing Activities is $187500.0 (2024), against an average of $18.9 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 6132.15% in 2022, then tumbled 13928.57% in 2023.
- Gossamer Bio's Cash from Financing Activities stood at -$2.9 million in 2022, then decreased by 1.04% to -$2.9 million in 2023, then surged by 109.68% to $281000.0 in 2024, then jumped by 1307.47% to $4.0 million in 2025, then slumped by 87.05% to $512000.0 in 2026.
- Business Quant data shows GOSS's Cash from Financing Activities at $512000.0 in Q1 2026, $4.0 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | -3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.14 Mn |
| Jun 30, 2026 | -3.14 Mn |
| Mar 31, 2026 | 512,000.00 |
| Mar 31, 2026 | 512,000.00 |
| Dec 31, 2025 | 3.96 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 94,000.00 |
| Mar 31, 2025 | 504,000.00 |
| Mar 31, 2025 | 504,000.00 |
| Sep 30, 2024 | 281,000.00 |
| Sep 30, 2024 | 281,000.00 |
| Jun 30, 2024 | -9.21 Mn |
| Jun 30, 2024 | -9.21 Mn |
| Mar 31, 2024 | -2.56 Mn |
| Mar 31, 2024 | -2.56 Mn |
| Dec 31, 2023 | -2.90 Mn |
| Dec 31, 2023 | -2.90 Mn |